ANOS1

anosmin 1, the group of Fibronectin type III domain containing|WAP four-disulfide core domain containing

Basic information

Region (hg38): X:8528874-8732137

Previous symbols: [ "KAL", "ADMLX", "KAL1" ]

Links

ENSG00000011201NCBI:3730OMIM:300836HGNC:6211Uniprot:P23352AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • hypogonadotropic hypogonadism 1 with or without anosmia (Strong), mode of inheritance: XL
  • Kallmann syndrome (Supportive), mode of inheritance: AD
  • hypogonadotropic hypogonadism 1 with or without anosmia (Definitive), mode of inheritance: XL

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Hypogonadotropic hypogonadism 1 with or without anosmia (Kallmann syndrome 1)XL/DigenicAudiologic/Otolaryngologic; EndocrineSurveillance in adolescence related to sexual maturation is indicated, as is monitoring of bone mineral density in order to allow early detection and treatment of disease; In order to induce and maintain secondary sex characteristics, gradually increasing doses of gonadal steroids (females: estrogen/progestin; males: testosterone/hCG) can be beneficial; Related to fertility, endocrinologic therapy (females: recombinant hCG or pulsatile GnRH therapy; males: hCG/HMG/recombinant FSH or pulsatile GnRH therapy) may be effective, though IVF may be required; As the condition may include hearing loss, recognition and interventions related to speech and language development may be beneficialAudiologic/Otolaryngologic; Craniofacial; Dental; Endocrine; Genitourinary; Musculoskeletal; Neurologic; Renal6772660; 3312278; 3101500; 8504298; 7677154; 8989261; 9713559; 10944855; 11297579; 15001591; 8768867; 16882753; 8160472; 20301509; 20949504; 23533228
Digenic inheritance (with PROKR2) has been reported

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the ANOS1 gene.

  • Hypogonadotropic hypogonadism 1 with or without anosmia (31 variants)
  • not provided (9 variants)
  • Martsolf syndrome 1 (1 variants)
  • Inborn genetic diseases (1 variants)
  • ANOS1-related disorder (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the ANOS1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
17
clinvar
9
clinvar
27
missense
4
clinvar
54
clinvar
10
clinvar
7
clinvar
75
nonsense
18
clinvar
2
clinvar
20
start loss
3
clinvar
3
frameshift
15
clinvar
2
clinvar
17
inframe indel
1
clinvar
1
splice donor/acceptor (+/-2bp)
1
clinvar
4
clinvar
1
clinvar
6
splice region
1
2
2
5
non coding
3
clinvar
18
clinvar
21
clinvar
42
Total 37 12 60 45 37

Variants in ANOS1

This is a list of pathogenic ClinVar variants found in the ANOS1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
X-8531911-CTAATTTGTAGCATAAAACATTTCCAAAAAGTAAGATATACTAGATTTGAAAGCATATGGGTGAATTAAATGCAAATAACTGTCCTTCTCTATCAATCAAAGGAATTTTTAAAACATTACCAATAATATTCTAGCACACAAAGACCTTTCTTTGATTAAGAAAAGGCAAATCTCTGCAAAGATTTAAACATGCTCAATAGTTGGGATTTTTTCATTTGAAGCAAGAAGTTTTGTGAATTTTCAGATGGTGAAACAAAAGTGCACCAAAAGCTATTATCTGCATTGAGGAAAATAAGGGAAAATATAAATAAGATAACATATCAGGAAAATCTCTCACATAATAGGATCAAATATTAAAAGGCATCCCCAAGAAATAATTTTCATTTCTCCAAGGTAAAATCTGATTAGCAGCTTATTTCATTGAGTTCCTCTGGCTTGGGTGTCTTTTGTAAATCATAATTTATAGAGGGAACTTTGATTTACCTTTGCATAAAGAGCAGCACAAGGTACTTAAAGTAGGAGCATTTTTAGATTTAAATTCGCTGGTATATTTTAGATTACACATTTTCATTTAAAAATCACCTAGGATAAAAATGATCTTAGGAAAGATTCAAAAAAACAAAGCTGTGTAATCTTAGTTGATTTTTCATATCGAATCAATAATTTAGTCAAAAATATATTTTATTGATTAGATTTACGCTTAGTGTTATGTGTGAATTGTGTATTTGTTACTCTCCTTTTTGGGGCGGAGTTTGGTGCTCCAAATTCAGGGAAAACTGAGTTCTGTTGTAATTCAATAGAAATGAGCGACACCATACATGAAAACAAAATTTAGCATTAAACAGGCCTATTCTTCATTTTCTCCATGCTTGTAGGGAACTGGTGTCTGTCTTCACCAATCTACTGTTTCTCACTTGTCTCCAGATGCGTCCATGATTGACAGAAGTTCTTCCTGCACTAAAGTCACATAGGAGAGTCCGGGCCTCTGAGCAGTTCCCACTGCCTCTGGAAGTGTGCATGTCTCGTGGCCGAAGTTCAACAAGCTTACACATCTGTGCAATTTCACAAAATCTTTTTGAACAGTTTAGTATCTTTCTGGAGAAGGCTTGTAATGATGTGGATGACGATGCTTAAGATGAGATCCTAAAAAGTGACAAAATATGTCAGTCACATCCATTTGTATGTATCAAATAAATGATAGAATTACCTTTATTTGTAGAAAAAGCACGAGACCCTGGCAAATGTTCCTTCCTATGACCATGTCTTTCCTATTCTGAATCTGAATGTACAACCACACTCTTTCTCTCCTTTTCCTGTTTTTCTCTTCCTCTTTGATGTCTTCCCAAACTATAAAATAACAAGAAAAAGAAGACAAGCTCCTTTCCTTAAGCTCACACTTATCCAATCAAACCATAATCCTTTTTTATTTGCTCAAAGAAGTTTAAAAATTATCAAATACTTCTGTTAAAAGGAATTTCTATGAAGGAATATCAGAAAAGCATTTATCTGACAAAAATTTTAGAGGCTATCAAGCTCTCCCATTGTGATAGTTTTTGTTTTTCTTCAAATTATAAGCATACCAAGTTATCAATTATAAGCATACCAATCTATCATTTAAAAAAATCAGAGTTAAAACTATGACTAATTCTCAATGTTTTGTCCACACACTAGTCATCAGACACTTTTTTAAAAAATTTAAGCTAGAAAATAAAGTAAACGAAGTACATAATTTAAAAATCAGCAAGAGGCTGTTTTGAAAATCTAGGTGACAATTTTCTTTTTAAATTTTACTTGATTTAGCAATAAATGAAGTAGGTGGACTTGGGTCATATCATGAAGAAAATTCATAATATTTATTACAGTAATATCTATGTAACAAGAACATAAGTTCCTTAGCAAAATATTATTTCCTATATTGTGATATATGAAAATCTTGATTTAAAAATATTTCAGATATGAGACTACAGATTTTTTTCCCATATGTATTTATGGTTTAAAAGACAAGGAAAAAAGCATGCATTACATAGGGGAAAATGCAAGGAAGGAAAAAAAAAACAAAGGAAGGATAGAGGAAAGGAGAAAAGAAGAGAGGGAAGAATGAAGGAGGGAGGGAGAGAGGATGGAGAAAGGAAACAAGGAAGGAGCAAAGAAAGGGAGAAAAGCGGGGAAGAGGGAGGGAGGGAGAAAAAGAACAATTAAGCATCAACTATGCAATGTATACTACAGGTGCCTGGAATAGAATCTAGTAAGTCGGTACAAACAGGGAGAAAGAATTTCAGATGATGACAATTTCCCTATCTCATAGAAACCTGTACTAGTGTATTTATTTGTTTTCATTTTCCAGCAAGATTTTTCTCTATGTCCACAAGACCTGACAGGATGGCTTAATGCCCTGGCACCCCACTCACTGTGTGCTGAAGAGGGTGGGAGCTCCGGCGTCCGGAACGTCTTGATGGTGGCCGGCCCCTCCCCTCCTGGGGTCAGCACTTGCACTTCCAGTCGGTAAAGAGTAGATGGTCTCAGATTGGGCACTGTTAGGACATAATGATCCTAAGGGGACAACATAAAAGAGCATGCTCACCGACAACCTTTCAGAGACAACATGCAATGCACAGAGAGCCTAGAACAGTTTTTCCCCCACTGGAGAATATCATACACAGGCAAGTTTGGTTGCTTTGTAAAGGCATAGTTTAATTTATAGACTATTTCTCATTTGTGGGGGTTCTCTGCCATATGGTTTCTTAGCACCTCACTCAATTCTTGGCAGCCTAAGACACTTGGCAGAGTTAAAATATGCTGAGGTGCCAGTTCTCAGGGCTCACTCCTGGGATTTTATTTATTTTTTTAATTCCTTAACGTAAAACTTTCCCATGGTTTAAAGTCTTCAGCTGCACATCTTGTGATGTGAACTCTTGATAGTCCAAATTTCAGTGAATGAGCCAACTGTTTTTCTTAAAACACAGTATCTGTCAATGCCCATAACTGAAAATGTTTATTTTTATGCCAACATATTCTTCTCAAAACTCAATAAAACCTAGTACATTTATAGAATAACTACTCTCTAATTCCATGGAATTTTTCCTTCTGAGATTTAAGTTGTGTTTCTTTCCCTCTCTGCCCCTCTTTTTGGATTTTGTAACGGTAGTTGGCTATTCTAAGGGCATTTTCAGAGAGGGTAAAATCCCACACATGATTTTTTTTTTTTTTTTTTGAAGCCAAGGAATTAAGTGGCCTGGAAGACAGGCCAACTCATTACAGCCTCGAGCCAA-C Hypogonadotropic hypogonadism 1 with or without anosmia Pathogenic (Jul 01, 1992)10002
X-8532889-C-T Likely benign (May 26, 2021)1342039
X-8532935-G-A Benign (Mar 03, 2015)1291184
X-8532999-T-C Hypogonadotropic hypogonadism 1 with or without anosmia Uncertain significance (Oct 08, 2020)1063327
X-8533023-T-C not specified • Hypogonadotropic hypogonadism 1 with or without anosmia • Amenorrhea Conflicting classifications of pathogenicity (Oct 03, 2023)224350
X-8533079-C-A Benign (Mar 03, 2015)1236328
X-8533252-C-T Benign (Apr 09, 2019)1228845
X-8533287-C-T Likely benign (Oct 25, 2020)1203979
X-8533991-AAAG-A Benign (Aug 13, 2019)1286210
X-8534047-G-A Benign (Jun 26, 2018)1273399
X-8534180-AG-A Benign (Mar 03, 2015)1238821
X-8534346-GCGTCCGGAA-G Hypogonadotropic hypogonadism 1 with or without anosmia Uncertain significance (Sep 01, 2022)1705413
X-8534348-G-T Hypogonadotropic hypogonadism 1 with or without anosmia Uncertain significance (Apr 20, 2017)438710
X-8534355-A-CG Hypogonadotropic hypogonadism 1 with or without anosmia Likely pathogenic (Sep 18, 2023)3256568
X-8534371-C-T Hypogonadotropic hypogonadism 1 with or without anosmia Likely benign (Oct 28, 2021)731395
X-8534382-C-T Hypogonadotropic hypogonadism 1 with or without anosmia Likely benign (Dec 31, 2019)704325
X-8534395-C-T Hypogonadotropic hypogonadism 1 with or without anosmia Likely benign (May 15, 2023)1092739
X-8534399-T-G Hypogonadotropic hypogonadism 1 with or without anosmia Likely pathogenic (Jan 03, 2017)375418
X-8534412-G-A Hypogonadotropic hypogonadism 1 with or without anosmia • Martsolf syndrome 1 Pathogenic (Sep 28, 2022)265206
X-8534412-GG-AA Hypogonadotropic hypogonadism 1 with or without anosmia Pathogenic (Feb 27, 2020)1069737
X-8534414-TAA-T Pathogenic (Sep 03, 2015)429739
X-8534420-G-A Uncertain significance (Feb 22, 2017)423915
X-8534432-A-C Hypogonadotropic hypogonadism 1 with or without anosmia Uncertain significance (Feb 27, 2020)1036587
X-8534440-C-CA Hypogonadotropic hypogonadism 1 with or without anosmia Pathogenic (Apr 16, 2021)1460215
X-8534451-C-T Hypogonadotropic hypogonadism 1 with or without anosmia Uncertain significance (May 25, 2022)1979197

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
ANOS1protein_codingprotein_codingENST00000262648 14203313
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.9980.00207125730531257380.0000318
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.8852212610.8460.00002054384
Missense in Polyphen5381.3170.651771462
Synonymous0.09281071080.9890.000009161371
Loss of Function4.69331.30.09580.00000283408

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00007310.0000731
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.00006260.0000462
European (Non-Finnish)0.00006160.0000440
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Has a dual branch-promoting and guidance activity, which may play an important role in the patterning of mitral and tufted cell collaterals to the olfactory cortex (By similarity). Chemoattractant for fetal olfactory epithelial cells. {ECO:0000250, ECO:0000269|PubMed:19696444}.;
Disease
DISEASE: Hypogonadotropic hypogonadism 1 with or without anosmia (HH1) [MIM:308700]: A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic- pituitary axis. In some cases, it is associated with non- reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH). {ECO:0000269|PubMed:11297579, ECO:0000269|PubMed:15001591, ECO:0000269|PubMed:15471890, ECO:0000269|PubMed:15605412, ECO:0000269|PubMed:17054399, ECO:0000269|PubMed:17213338, ECO:0000269|PubMed:17223984, ECO:0000269|PubMed:19696444, ECO:0000269|PubMed:20530987, ECO:0000269|PubMed:21168128, ECO:0000269|PubMed:23643382, ECO:0000269|PubMed:25077900, ECO:0000269|PubMed:8504298, ECO:0000269|PubMed:8989261, ECO:0000269|PubMed:9589672}. Note=The disease is caused by mutations affecting distinct genetic loci, including the gene represented in this entry. The genetics of hypogonadotropic hypogonadism involves various modes of transmission. Oligogenic inheritance has been reported in some patients carrying mutations in ANOS1 as well as in other HH-associated genes including FGFR1 and TACR3 (PubMed:23643382). {ECO:0000269|PubMed:23643382}.;
Pathway
Signal Transduction;Signaling by FGFR;Signaling by Receptor Tyrosine Kinases;FGFR1c ligand binding and activation;FGFR1 ligand binding and activation;Negative regulation of FGFR1 signaling;Signaling by FGFR1 (Consensus)

Recessive Scores

pRec
0.206

Intolerance Scores

loftool
rvis_EVS
0.15
rvis_percentile_EVS
64.74

Haploinsufficiency Scores

pHI
0.494
hipred
Y
hipred_score
0.784
ghis
0.413

Essentials

essential_gene_CRISPR
essential_gene_CRISPR2
essential_gene_gene_trap
N
gene_indispensability_pred
gene_indispensability_score

Zebrafish Information Network

Gene name
anos1a
Affected structure
neuromast hair cell
Phenotype tag
abnormal
Phenotype quality
decreased amount

Gene ontology

Biological process
chemotaxis;cell adhesion;axon guidance;fibroblast growth factor receptor signaling pathway;negative regulation of endopeptidase activity
Cellular component
extracellular region;extracellular space;plasma membrane;extracellular matrix
Molecular function
serine-type endopeptidase inhibitor activity;extracellular matrix structural constituent;protein binding;heparin binding